10x Genomics unveiled its Atera spatial instrument at AACR 2026, positioning the platform as whole-transcriptome spatial biology at scale. The company says Atera addresses trade-offs seen with existing spatial tools by increasing throughput, multiplexing capacity, and sensitivity for whole transcriptome workflows. Coverage specifies Atera’s performance comparisons against Xenium, including higher throughput and greater plex capabilities for targeted assays, alongside whole-transcriptome imaging and runtime claims. 10x also announced pricing at $495,000, with orders taking place now and availability planned for the second half of the year. For translational researchers, the operational question is speed-to-data and tissue throughput—especially for FFPE and fresh frozen workflows—where spatial omics can influence biomarker development and preclinical model design.